Skip to main content

Table 1 Baseline patient characteristics

From: Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel

Characteristic Omeprazole group (n = 303) Pantoprazole group (n = 304) P value
Age (year) 59.15 ± 8.75 58.76 ± 8.50 0.58
Male [n (%)] 209 (69.0) 215 (70.7) 0.66
Cardiovascular risk factors
 BMI (kg/m2) 25.57 ± 3.86 25.54 ± 3.43 0.92
 Hypertension [n (%)] 199 (65.7) 186 (61.2) 0.27
 Dyslipidemia [n (%)] 135 (44.6) 125 (41.1) 0.41
 Diabetes mellitus [n (%)] 84 (27.7) 82 (27.0) 0.86
 Active smoking [n (%)] 170 (56.1) 171 (56.3) 1.00
 Previous myocardial infarction [n (%)] 48 (15.8) 46 (15.1) 0.82
 Previous transient ischemic attack/stroke [n (%)] 27 (8.9) 27 (8.9) 1.00
Final clinical diagnosis [n (%)]
 UA 262 (84.3) 264 (86.8) 0.90
 NSTEMI 42 (13.9) 39 (12.8) 0.72
Laboratory parameters
 WBC (×1012/L) 7.01 ± 1.85 6.91 ± 1.74 0.48
 RBC (×109/L) 6.04 ± 0.34 4.52 ± 0.55 0.32
 PLT (×1012/L) 211.16 ± 51.24 210.42 ± 51.89 0.86
 Hb (g/L) 140.66 ± 15.19 141.24 ± 13.87 0.67
 Creatinine (mg/dl) 71.73 ± 23.13 69.77 ± 22.95 0.27
 CRP (mmol/L) 3.73 ± 6.47 4.82 ± 17.54 0.59
 TNT (ng/ml) 0.08 ± 0.32 0.07 ± 0.31 0.62
 Blood glucose (mmol/L) 6.40 ± 2.46 6.75 ± 3.39 0.21
 Total cholesterol (mmol/L) 3.88 ± 1.05 3.86 ± 0.99 0.82
 Total triglycerides (mmol/L) 1.97 ± 1.32 1.92 ± 1.42 0.95
 Low-density lipoprotein cholesterol (mmol/L) 2.18 ± 0.95 2.14 ± 0.87 0.56
 High-density lipoprotein cholesterol (mmol/L) 1.09 ± 0.72 1.11 ± 0.80 0.80
 Baseline ADP-PA (%) 60.00 ± 20.87 57.50 ± 19.73 0.13
  1. BMI Body mass index, UA Unstable angina, NSTEMI Non-ST segment elevation myocardial infarction, WBC White blood cell, RBC Red blood cell, PLT Platelet, Hb Hemoglobin, CRP C-reactive protein, ADP-PA Adenosine diphosphate-induced platelet aggregation